Insider buying last 90 days
$1.06Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Jul 31 | Michael R Hayden Director | Purchase | $801K |
| Jul 31 | Michael R Hayden Director | Purchase | $258K |
From Form 4 filings, dated to when each was filed.
NASDAQ: IONS
Ionis Pharmaceuticals (IONS) Stock Analysis & Forecast
Sep 28 close
$45.57+1.07 (+2.4%)
Gekko Brief
AI summaryThis week Ionis and partner Roche reported positive prespecified interim Phase 3 results for sefaxersen in IgA nephropathy, showing a statistically significant reduction in proteinuria versus placebo at week 37 in the IMAgINATION study. Alongside this, Ionis and Otsuka announced positive Phase 3 FUSION trial results for ulefnersen in FUS-ALS, with the drug meeting its primary endpoint on functional impairment and survival and showing favorable secondary endpoints, with Ionis noting it will seek expedited FDA review. An 8-K filing dated 23 September was also noted alongside these clinical updates.
IONS closed at $45.57, up 2.4% on the day, though the stock remains below both its 50-day average of $54.67 and its 200-day average of $71.09, with the 50-day below the 200-day. Longer-term returns show declines across the 1-month, 3-month, 6-month and 1-year periods. The GekkoIndex reads 66.4, placing the stock in the Accumulation zone, while price sits 30.5% below Gekko Fair Value of $65.61.
Over the next 20 trading days, the next earnings date falls on 4 November 2026, 36 days away, outside a typical holding window of this length. In the last 90 days there have been 2 open-market insider purchases totaling $1,058,700. Seasonality over 5 years shows an average 20-day return of -1.2% from this point in the calendar, rising in 1 of those years. Consensus among 21 firms stands at 17 buy, 4 hold, 0 sell, with a consensus target of $83.64.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Ionis Pharmaceuticals price vs fair value
Close $45.57200-day averageGekko Fair Value $65.61
Ionis Pharmaceuticals quick facts
- Market cap
- $7.57B
- P/E ratio
- —
- Forward P/E
- 90.9
- EPS, TTM
- −$3.48
- Revenue, TTM
- $874.1M
- Profit margin
- -64.7%
- Dividend yield
- —
- Beta
- 0.42
- Volume
- 3.55M avg 4.43M
- 1-year return
- −27.6%
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±6.2%
- 50-day average
- $54.67
- 200-day average
- $71.09
- Next earnings
- Nov 4
- Shares outstanding
- 166.2M
Ionis Pharmaceuticals swing-trade checklist
Ionis Pharmaceuticals scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $45.57 is below the 50-day ($54.67) and 200-day ($71.09) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
66.4, Accumulation
Reading 66.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
30.5% below
Price is 30.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.2% on average
From this point in the calendar, the next 20 trading days averaged −1.2% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Ionis Pharmaceuticals stock chart and price history
Ionis Pharmaceuticals closed at $45.57 on Sep 28, 2026, −27.6% over the past year, inside a 52-week range of $43.01 to $86.74.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −27.0%
- 3 months
- −43.5%
- 6 months
- −36.8%
- 1 year
- −27.6%
The full IONS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IONS in Gekko
Follow Ionis Pharmaceuticals through every session
Put IONS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IONS in GekkoFree for 7 days. No credit card required.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals works on medicines built around RNA-targeting technology, focused on treating rare and genetic conditions. Its marketed products include a therapy for spinal muscular atrophy, an injectable for a nerve condition linked to hereditary transthyretin-mediated amyloidosis, and a treatment for two rare lipid disorders. The company has become associated with this RNA-based approach to drug design.
Beyond its approved medicines, Ionis runs a pipeline of candidates in late-stage trials, covering conditions such as TTR amyloidosis, severe high triglycerides, hereditary angioedema, ALS, cardiovascular disease tied to elevated lipoprotein(a), and a genetic form of ALS treated through inhibiting a specific protein's production. It also researches treatments in metabolic, infectious, renal, ophthalmic and oncology areas. Much of its work is carried out through partnerships, including a strategic collaboration with Biogen, along with licensing and collaboration agreements with AstraZeneca, Bayer, GlaxoSmithKline, Novartis, Roche, Janssen Biotech and Flamingo Therapeutics.
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California. Its shares are listed on the NASDAQ under the ticker IONS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- ionis.com
Ionis Pharmaceuticals GekkoIndex: the smart money zone
Ionis Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.4, in the Accumulation zone, down 6.7 points over five sessions.
66.4Accumulation
Down 6.7 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | +0.3% | +2.7% | ||
| Accumulation (current zone) | 231 | −0.6% | −0.6% | ||
| Neutral | 346 | +0.6% | +1.6% | ||
| Distribution | 38 | −0.5% | +1.9% | ||
| Selling | 5 | Too few readings yet | |||
Average IONS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the IONS price, zone by zone.Track IONS in Gekko
Is Ionis Pharmaceuticals stock overvalued? Gekko Fair Value
Ionis Pharmaceuticals trades 30.5% below Gekko Fair Value of $65.61, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Ionis Pharmaceuticals shares are worth, recalculated every trading day.
$65.61
Gekko Fair Value, Sep 29, 2026
30.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open IONS in Gekko
Ionis Pharmaceuticals insider and Congress trading
Insiders filed 2 open-market purchases in Ionis Pharmaceuticals worth $1.06M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IONS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IONS, plotted on the chart in Gekko.Open IONS in Gekko
Buybacks
Ionis Pharmaceuticals has been buying back its own shares.
- Bought back, year ended Dec 31, 2020
- $90.55M
- As a share of market cap
- 1.20%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds IONS.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Ionis Pharmaceuticals earnings: next date and track record
Ionis Pharmaceuticals reports on Nov 4, 2026 (36 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
36 days away
- EPS estimate
- −$1.21
- Revenue estimate
- $182.4M
7 of 8reports beat the EPS estimate
±3.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Ionis reported strong commercial and R&D momentum in Q2 2026 highlighted by the FDA approval and initial launch of TRYNGOLZA for severe hypertriglyceridemia (sHTG), continued uptake of DAWNZERA in hereditary angioedema, preparation for the upcoming Zilganersen launch in Alexander disease, and advancement of several pipeline programs (e.g., ION775, ION337). Financial results showed significant year-over-year revenue growth (Q2 $268M, H1 $514M), with commercial revenue growth driven by DAWNZERA and early TRYNGOLZA sales; R&D revenue from partners remained meaningful. Management emphasized early positive launch metrics for TRYNGOLZA despite an April 1 WAC price reduction implemented to support payer contracting and broader sHTG access. The company ended Q2 with ~$2.1B in cash and reiterated confidence in execution, upcoming catalysts (HORIZON/Pelacarsen readout, ESC and OLE data), and medium-term commercial opportunities.
- Guidance
- Management reiterated full-year TRYNGOLZA revenue expectation of $100 million to $110 million for the year and stated they expect TRYNGOLZA revenues to return to growth in the second half of 2026 as the sHTG launch gains momentum. Management also reiterated an objective to achieve cash flow breakeven by 2028 (goal, not formal financial guidance).
- Risks flagged
- Reimbursement and payer access (medical exceptions early in launch, need for prior authorizations), lack of a dedicated ICD-10 code for sHTG potentially complicating reimbursement, potential negative impact if Pelacarsen (HORIZON) Phase III is not positive which could pressure the ability to achieve cash flow breakeven in 2028, the April 1 WAC price reduction temporarily reduced TRYNGOLZA revenue in Q2, and general clinical/trial execution and competitive risks.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$0.70 est −$1.09 | $268.0M est $189.1M | −3.7% |
| Apr 29, 2026 | −$0.30 est −$0.77 | $246.0M est $195.6M | +4.2% |
| Feb 25, 2026 | −$1.41 est −$1.24 | $203.0M est $156.1M | −5.7% |
| Oct 29, 2025 | −$0.61 est −$1.15 | $156.7M est $153.6M | +0.8% |
| Jul 30, 2025 | $0.86 est $0.27 | $452.0M est $131.7M | +3.6% |
| Apr 30, 2025 | −$0.93 est −$1.13 | $131.6M est $150.6M | +6.4% |
| Feb 19, 2025 | −$0.43 est −$0.84 | $226.6M est $131.1M | +2.3% |
| Nov 6, 2024 | −$0.95 est −$1.16 | $133.8M est $144.4M | −0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Ionis Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Ionis Pharmaceuticals is $83.64, +83.5% from the last close, from 21 firms rating the stock in the last 90 days.
$83.64consensus 12-month target, +83.5% from the last close
Now $45.57Avg $83.64
Low $54High $104
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | H.C. Wainwright | $100 | +119.4% |
| Sep 24 | Canaccord Genuity | $85 | +86.5% |
| Sep 24 | Oppenheimer | $85 | +86.5% |
| Sep 23 | Needham | $86 | +88.7% |
| Sep 23 | TD Cowen | $84 | +84.3% |
−0.6%average 20-day move after past Accumulation readings
−1.2%average move over the next 20 trading days in the last 5 years
±5.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Ionis Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Ionis Pharmaceuticals averaged −1.2% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.0% | 3 of 5 |
| Next 10 trading days | +2.6% | 3 of 5 |
| Next 15 trading days | +1.1% | 3 of 5 |
| Next 20 trading days | −1.2% | 1 of 5 |
| Next 30 trading days | +1.7% | 3 of 5 |
For scale, IONS’s typical 20-trading-day move in either direction is about 6.2%.
Ionis Pharmaceuticals market cap and key statistics
Ionis Pharmaceuticals’s market cap is $7.57B and revenue of $874.1M over the last twelve months.
Valuation
- Market cap
- $7.57B
- Forward P/E
- 90.9
- EPS, TTM
- −$3.48
- Gekko Fair Value
- $65.61
Trading
- Volume
- 3.55M
- Avg volume, 20 days
- 4.43M
- 52-week high
- $86.74
- 52-week low
- $43.01
- Shares outstanding
- 166.2M
Financials
- Revenue, TTM
- $874.1M
- Profit margin
- -64.7%
- Return on equity
- -105.5%
- Quarterly earnings growth, YoY
- −43.7%
Risk and income
- Beta
- 0.42
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±6.2%
Ionis Pharmaceuticals stock news this week
Coverage of Ionis Pharmaceuticals this week reads positive: 6 positive, 1 neutral and 0 negative headlines.
- Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.comInvesting.com Nigeria, Sep 24
- Roche, Ionis RNA drug scores in kidney disease studyBioPharma Dive, Sep 23
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsZacks Investment Research, Sep 23
- Ionis to Seek Expedited FDA Review for ALS DrugBenzinga, Sep 23
- Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathyTradingView, Sep 23
- Ionis Phase 3 sefaxersen trial meets IgAN endpointMugglehead Investment Magazine, Sep 23
Ionis Pharmaceuticals peers
Ionis Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Ionis Pharmaceuticals stock FAQ
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $7.57B at the Sep 28, 2026 close of $45.57, with 166.2M shares outstanding.
What is the Ionis Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Ionis Pharmaceuticals is $83.64, +83.5% from the last close. Of the 21 firms that rated the stock in the last 90 days, 17 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Ionis Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Ionis Pharmaceuticals is undervalued: the Sep 28, 2026 close of $45.57 is 30.5% below Gekko Fair Value of $65.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Ionis Pharmaceuticals report earnings next?
Ionis Pharmaceuticals is expected to report on Nov 4, 2026 (36 days away). Analysts expect earnings of −$1.21 per share on revenue of $182.4M. Ionis Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 3.5% on average across the report.
What is Ionis Pharmaceuticals’s 52-week high and low?
Ionis Pharmaceuticals’s 52-week high is $86.74 and its 52-week low is $43.01; it closed at $45.57 on Sep 28, 2026, −27.6% over the past year.
Is Ionis Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Ionis Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.